
Low expression
High expression
Survival Probability
0.0
0.2
0.4
0.6
0.8
1.0
0
20
40
60
80
100
120
Time in Month

FIGURE 1A


Survival Probability
0.0
0.2
0.4
0.6
0.8
1.0
0
20
40
60
80
Time in Month
Low expression
High expression

FIGURE 1B


Survival probability
1.0
0.8
0.6
0.4
0.2
0.0
Low expression
High expression
0
50
100
150
Time in month

FIGURE 1C


Immune Cell
Fc-Receptor
TIGIT
DNAM1
PD-1
Activation Signal
Inhibition Signal
PVR
Nectin-2
PD-1L
Tumor Cell

FIGURE 2



FIGURE 3A



FIGURE 3B



FIGURE 3C



FIGURE 3D



FIGURE 4


Specific Killing
70
60
50
40
30
20
10
0
*
***
***
No
anti-PVR 4E5
anti-PVR 4e5hIgG1
Erbitux (P.C)

FIGURE 5



FIGURE 6A



FIGURE 6B



FIGURE 6C



FIGURE 6D


Anti Nectin-2
Anti PVR
Count
51
38
26
13
0
10^0
10^1
10^2
10^3
10^4
FL4-H

FIGURE 6E



FIGURE 6G



FIGURE 6F



FIGURE 6H



FIGURE 6J



FIGURE 6I



FIGURE 6L



FIGURE 6K



FIGURE 6M

FIGURE 6N



FIGURE 6O



FIGURE 7A



FIGURE 7B



FIGURE 7C



FIGURE 7D



FIGURE 8A



FIGURE 8B



FIGURE 8C


Anti hPVR mABs
hTIGIT -Fc
Count
18
14
9
5
0
10^0
10^1
10^2
10^3
10^4
FL4-H

FIGURE 9



FIGURE 10A



FIGURE 10B



FIGURE 10C



FIGURE 10D


Fold Induction Proliferation
2.8
2.6
2.4
2.2
2
1.8
1.6
1.4
1.2
1
0.8
No mAb
mIgG
PVR-4E5
PVR-5B9
PD-1
CTLA-4
4E5hIgG1

FIGURE 11


Fold induction proliferation
3.2
3
2.8
2.6
2.4
2.2
2
1.8
1.6
1.4
1.2
1
0.8
No mAb
mIgG
PD-1+CTLA4
PD-1+4E5
PD-1+5B9
CTLA4+PVR4E5
CTLA4+PVR5B9

FIGURE 12


Fold induction proliferation
4.5
3.75
3
2.25
1.5
0.75
mIgG
No mAb
PD1
CTLA4
PVR4E5
PVR5B9
PVR7D4
PVR4E5hIgG1
PVR5B9hIgG1
PVR7D4hIgG1

FIGURE 13


CD8/CD4 ratio
2
1.6
1.2
0.8
0.4
0
mIgG
No mAb
PD1
CTLA4
PVR4E5
PVR5B9
PVR7D4
PVR4E5hIgG1
PVR5B9hIgG1
PVR7D4hIgG1

FIGURE 14


Fold induction degranulation
3.8
3.55
3.3
3.05
2.8
2.55
2.3
2.05
1.8
1.55
1.3
1.05
0.8
NomAb
mIgG
PVR 4E5
PVR 5B9
PVR 7d4
PVR 4E5hIgG1
PVR 5B9hIgG1
PVR 7d4hIgG1

FIGURE 15


A549
***
Relative survival
1.2
1
0.8
0.6
0.4
0.2
0
No mAb
mIgG
m4E5
5B9
7D4

FIGURE 16A


U373
Relative survival
1.4
1.2
1
0.8
0.6
0.4
0.2
0
***
No mAb
mIgG
m4E5
5B9
7D4

FIGURE 16B


HCT116
Relative Survival
1.2
1
0.8
0.6
0.4
0.2
0
***
No mAb
mIgG
m4E5
5B9
7D4

FIGURE 16C


Mel-624
Relative Survival
1.4
1.2
1
0.8
0.6
0.4
0.2
0
**
No mAb
mIgG
m4E5
5B9
7D4

FIGURE 16D